Tiltan Pharma

Tiltan's drug combination

A Drug Combination

Consists of low-dose, high - frequency alkylating agent with 3 non-cytotoxic agents

 

Most of the cancer targeted therapies do not work as stand-alone but are administered on top of additional drug/s, mainly chemotherapies

Patient Friendly

Oral, daily, can be taken at home

 

Taste masking

 

No need for hospitalization

 

 

Combined

Mode of Action

Metronomic chemotherapy

 

Anti-angiogenic multi-faceted therapy

 

Immuno- modulatory therapy

Superior Clinical Development

Relatively short time to market due to 505B2 regulatory path

 

 

4 Approved Drugs Repurposed

All FDA approved drugs with known safety and pharmacokinetic  profiles

 

In addition to immuno-modulatory known activity the combination  immerged as an anti cancer therapy

Life Cycle Management

Potential for development in a broad spectrum of solid tumors

 

Potential for combi-nation with other SOC and anti-angiogenic therapies

Global IP Protection

IP covering :

Combination`s composition

Components` relative ratio

Unit-dose formulation (liquid form)

Dose regimen

and scheduling

 

Lower Cost Production

Generic drug substances, compared to high cost biological approved drugs

 

Advantage in a compe-titive environment

Will lead to a larger market-share

 

 

icon of an envelope icon of a house

Built by Badboy.co.il

© copyright 2015 Tiltan Pharma